Acquired drug resistance conferred by a KRAS gene mutation following the administration of cetuximab: a case report.
Acquired drug resistance conferred by a KRAS gene mutation following the administration of cetuximab: a case report.
复制标题
DOI：
10.1186/1756-0500-6-508
复制
发表时间：
2013-12-05
影响因子：
1.8
通讯作者：
Yamaguchi T
中科院分区：
文献类型：
--
作者：
Osumi H;Matsusaka S;Shinozaki E;Suenaga M;Mingyon M;Saiura A;Ueno M;Mizunuma N;Yamaguchi T
尽管许多研究报告了由于给予表皮生长因子受体抗体抑制剂而导致的获得性耐药性，但这种现象的根本原因仍不清楚。我们在此报告一例75岁男性患者，在成功行横结肠切除术治疗KRAS野生型结直肠癌后3年出现肝转移。虽然表皮生长因子受体抑制剂的初始给药被证明是有效的，但继续使用相同的治疗导致新的腹膜种植。在来自一个这样的区域的切除组织标本中发现了获得性KRAS突变。这种突变，可能是由管理引起的表皮生长因子受体抑制剂，似乎已经赋予耐药性。目前的研究结果表明，表皮生长因子受体抑制剂的管理结果在获得性KRAS突变，赋予耐药性。
Although a number of studies have reported acquired drug resistance due to administration of epidermal growth factor receptor antibody inhibitors, the underlying causes of this phenomenon remain unclear. Here we report a case of a 75-year-old man with liver metastasis at 3 years after a successful transverse colectomy to treat KRAS wild-type colorectal cancer. While initial administration of epidermal growth factor receptor inhibitors proved effective, continued use of the same treatment resulted in new peritoneal seeding. An acquired KRAS mutation was found in a resected tissue specimen from one such area. This mutation, possibly caused by administration of epidermal growth factor receptor inhibitors, appears to have conferred drug resistance. The present findings suggest that administration of epidermal growth factor receptor inhibitors results in an acquired KRAS mutation that confers drug resistance.